MedTrace Logo

Topical Insulin for Glaucoma

NCT05206877 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-11-25

No results posted yet for this study

Summary

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Conditions

Interventions

DRUG

Insulin, 4 units

Topical insulin 100 U/ml, 1 drop per day

DRUG

Insulin, 20 units

Topical insulin 500 U/ml, 1 drop per day

DRUG

insulin, 4 units twice daily

1 drop of low dose insulin twice daily.

DRUG

insulin, 20 units twice daily

1 drop of high dose insulin twice daily

DRUG

insulin, 4 units three times daily

1 drop of low dose insulin three times daily.

DRUG

insulin, 20 units three times daily

1 drop of high dose insulin three times daily.

Sponsors & Collaborators

Principal Investigators

  • Jeffrey L Goldberg, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05206877 on ClinicalTrials.gov